

MERRIMACK PHARMACEUTICALS INC

Form 8-K

November 30, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 26, 2017**

**Merrimack Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

|                                                        |                                        |                                           |
|--------------------------------------------------------|----------------------------------------|-------------------------------------------|
| <b>Delaware</b><br><b>(State or Other Jurisdiction</b> | <b>001-35409</b><br><b>(Commission</b> | <b>04-3210530</b><br><b>(IRS Employer</b> |
| <b>of Incorporation)</b>                               | <b>File Number)</b>                    | <b>Identification No.)</b>                |

**One Kendall Square, Suite B7201**

|                                                                         |                                   |
|-------------------------------------------------------------------------|-----------------------------------|
| <b>Cambridge, MA</b><br><b>(Address of Principal Executive Offices)</b> | <b>02139</b><br><b>(Zip Code)</b> |
|-------------------------------------------------------------------------|-----------------------------------|

**Registrant's telephone number, including area code: (617) 441-1000**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On November 26, 2017, John Mendelsohn, M.D. provided notice of his resignation from the Board of Directors (the Board ) of Merrimack Pharmaceuticals, Inc. (the Company ), effective as of November 29, 2017.

(d) On November 29, 2017, the Board elected George Demetri, M.D. as a director of the Company to fill the vacancy created by the resignation of Dr. Mendelsohn. Dr. Demetri was also elected to serve on the Organization and Compensation Committee of the Board.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MERRIMACK PHARMACEUTICALS, INC.

Date: November 30, 2017

By: /s/ Jeffrey A. Munsie  
Jeffrey A. Munsie

General Counsel